Petros Pharmaceuticals, Inc. (PTPI)
USD 0.05
(-3.36%)
USD 0.05
(-3.36%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 17.8 Million USD | -40.3% |
| 2022 | 19.54 Million USD | -19.42% |
| 2021 | 24.25 Million USD | 6.43% |
| 2020 | 22.79 Million USD | -8.89% |
| 2019 | 25.01 Million USD | 122.97% |
| 2018 | 11.22 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 4.65 Million USD | 3.04% |
| 2024 Q2 | 2.65 Million USD | -27.51% |
| 2023 Q2 | 3.94 Million USD | 20.34% |
| 2023 Q3 | 5.66 Million USD | 43.66% |
| 2023 FY | 11.67 Million USD | -40.3% |
| 2023 Q4 | 4.51 Million USD | -20.27% |
| 2023 Q1 | 3.27 Million USD | -18.45% |
| 2022 FY | 19.54 Million USD | -19.42% |
| 2022 Q4 | 4.01 Million USD | -10.07% |
| 2022 Q3 | 4.46 Million USD | -14.06% |
| 2022 Q2 | 5.19 Million USD | -11.34% |
| 2022 Q1 | 5.86 Million USD | -14.55% |
| 2021 FY | 24.25 Million USD | 6.43% |
| 2021 Q4 | 6.86 Million USD | 26.55% |
| 2021 Q3 | 5.42 Million USD | -14.54% |
| 2021 Q2 | 6.34 Million USD | 12.71% |
| 2021 Q1 | 5.62 Million USD | 2.25% |
| 2020 FY | 22.79 Million USD | -8.89% |
| 2020 Q4 | 5.5 Million USD | 14.25% |
| 2020 Q3 | 4.81 Million USD | -17.66% |
| 2020 Q2 | 5.85 Million USD | -11.55% |
| 2020 Q1 | 6.61 Million USD | -15.81% |
| 2019 Q1 | 5.69 Million USD | 0.0% |
| 2019 Q4 | 7.85 Million USD | 13.31% |
| 2019 FY | 25.01 Million USD | 122.97% |
| 2019 Q3 | 6.93 Million USD | -0.58% |
| 2019 Q2 | 6.97 Million USD | 22.61% |
| 2018 FY | 11.22 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 159.2 Million USD | 88.814% |
| Embecta Corp. | 528.4 Million USD | 96.63% |
| ANI Pharmaceuticals, Inc. | 195.98 Million USD | 90.913% |
| Dynavax Technologies Corporation | 219.14 Million USD | 91.874% |
| Esperion Therapeutics, Inc. | 271.89 Million USD | 93.45% |
| Pacira BioSciences, Inc. | 326.37 Million USD | 94.544% |
| PainReform Ltd. | 9.58 Million USD | -85.815% |
| Aquestive Therapeutics, Inc. | 44.85 Million USD | 60.297% |
| Sunshine Biopharma, Inc. | 13.12 Million USD | -35.69% |
| SCYNEXIS, Inc. | 51.84 Million USD | 65.652% |
| China SXT Pharmaceuticals, Inc. | 3.06 Million USD | -480.236% |
| Cosmos Health Inc. | 26.18 Million USD | 31.979% |
| Journey Medical Corporation | 54.59 Million USD | 67.38% |
| Sunshine Biopharma, Inc. | 13.12 Million USD | -35.69% |
| Safety Shot Inc | 12.1 Million USD | -47.06% |
| Alpha Teknova, Inc. | 45.85 Million USD | 61.167% |
| Intra-Cellular Therapies, Inc. | 590 Million USD | 96.982% |
| Bright Green Corporation | 8.25 Million USD | -115.786% |
| Procaps Group, S.A. | 199.47 Million USD | 91.072% |
| Theratechnologies Inc. | 72.75 Million USD | 75.523% |
| Harrow Health, Inc. | 89.97 Million USD | 80.207% |
| Sonoma Pharmaceuticals, Inc. | 9.44 Million USD | -88.53% |
| Biofrontera Inc. | 39.95 Million USD | 55.433% |
| DURECT Corporation | 43.71 Million USD | 59.262% |
| Supernus Pharmaceuticals, Inc. | 529.01 Million USD | 96.634% |
| Cronos Group Inc. | 96.7 Million USD | 81.585% |
| OptiNose, Inc. | 85.1 Million USD | 79.074% |
| Ironwood Pharmaceuticals, Inc. | 232.12 Million USD | 92.328% |
| Kala Pharmaceuticals, Inc. | 39.15 Million USD | 54.516% |
| RedHill Biopharma Ltd. | -9.56 Million USD | 286.262% |
| Organogenesis Holdings Inc. | 314.13 Million USD | 94.331% |
| Guardion Health Sciences, Inc. | 9.73 Million USD | -83.011% |
| Cumberland Pharmaceuticals Inc. | 43.04 Million USD | 58.624% |
| Radius Health, Inc. | 265.92 Million USD | 93.303% |
| Universe Pharmaceuticals INC | 13.84 Million USD | -28.657% |
| ProPhase Labs, Inc. | 37.85 Million USD | 52.952% |
| Phibro Animal Health Corporation | 260.29 Million USD | 93.158% |
| Procaps Group S.A. | 187.24 Million USD | 90.489% |
| Alvotech | 285.43 Million USD | 93.761% |
| TherapeuticsMD, Inc. | 9.82 Million USD | -81.257% |
| Viatris Inc. | 5.96 Billion USD | 99.702% |
| Rockwell Medical, Inc. | 15.37 Million USD | -15.835% |
| Aytu BioPharma, Inc. | 59.84 Million USD | 70.24% |
| SIGA Technologies, Inc. | 22.04 Million USD | 19.21% |
| Tilray Brands, Inc. | 251.35 Million USD | 92.915% |
| Lifecore Biomedical, Inc. | 49.03 Million USD | 63.684% |
| Shineco, Inc. | 17.94 Million USD | 0.777% |
| PetIQ, Inc. | 192.72 Million USD | 90.76% |
| Regencell Bioscience Holdings Limited | 3.99 Million USD | -346.202% |
| Incannex Healthcare Limited | 30.05 Million USD | 40.743% |
| Neurocrine Biosciences, Inc. | 1.59 Billion USD | 98.885% |
| Alimera Sciences, Inc. | 62.64 Million USD | 71.57% |
| Silver Spike Investment Corp. | 762.49 Thousand USD | -2235.57% |
| Assertio Holdings, Inc. | 368.58 Million USD | 95.168% |
| Shuttle Pharmaceuticals Holdings, Inc. | 5.88 Million USD | -202.58% |
| Clever Leaves Holdings Inc. | 21.16 Million USD | 15.874% |
| Cyclo Therapeutics, Inc. | 21.04 Million USD | 15.367% |
| Avadel Pharmaceuticals plc | 164.96 Million USD | 89.205% |
| Hempacco Co., Inc. | 7.59 Million USD | -134.432% |
| Talphera, Inc. | 11.99 Million USD | -48.479% |
| Alvotech | 285.43 Million USD | 93.761% |
| Eagle Pharmaceuticals, Inc. | 140.71 Million USD | 87.344% |
| Lantheus Holdings, Inc. | 344.9 Million USD | 94.837% |
| Currenc Group, Inc. | 24 Million USD | 25.804% |
| Kamada Ltd. | 45.42 Million USD | 60.797% |
| Indivior PLC | 911 Million USD | 98.045% |
| Evoke Pharma, Inc. | 12.4 Million USD | -43.506% |
| Flora Growth Corp. | 10.57 Million USD | -68.339% |
| Cyclo Therapeutics, Inc. | 21.04 Million USD | 15.367% |
| Evolus, Inc. | 189.75 Million USD | 90.615% |
| HUTCHMED (China) Limited | 436.23 Million USD | 95.918% |
| Amphastar Pharmaceuticals, Inc. | 154.13 Million USD | 88.446% |
| Akanda Corp. | 3.48 Million USD | -411.224% |